View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
August 9, 2009

OmniComm Systems To Provide eClinical Solutions For Phase I HIV Trials

HIV studies are expected to run for approximately seven months

By CBR Staff Writer

OmniComm Systems has announced that a major West coast biopharmaceutical company has selected OmniComm to provide eClinical solutions for two of its phase I HIV studies. Both HIV studies, involving over 100 patients, are expected to run for approximately seven months. OmniComm Systems has completed extensive work with this client in different therapeutic areas.

Stephen Johnson, COO of OmniComm, said: This latest contract, awarded to us by a major Biotech company reemphasizes the high value of the overall service offerings we bring to our clients. Our continued ability to provide uniquely tailored state of the art e-clinical solutions to life science companies is what distinguishes us from other EDC providers. Our products allow companies involved in clinical research, to stay competitive in the current healthcare market while significantly improving their operational efficiencies.

We will continue to add products and services to our mix to not only optimize the value to our customers, but to also generate additional revenue and increase shareholder value, he added.

Content from our partners
Rethinking cloud: challenging assumptions, learning lessons
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU